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Background: The role of DNA methylation in musculoskeletal diseases is poorly understood.
Results:Methylation of specific CpG sites in theMMP13 and IL1B promoters correlates strongly with gene activity in human
cartilage.
Conclusion: Specific CpG site methylation inhibitsMMP13 transactivation by HIF-2.
Significance: Our findings offer new insight on the impact of epigenetic control of a joint disease that can affect adults
throughout life.
The role of DNA methylation in the regulation of catabolic
genes such asMMP13 and IL1B, which have sparse CpG islands,
is poorly understood in the context of musculoskeletal diseases.
We report that demethylation of specific CpG sites at 110 bp
and 299 bp of the proximal MMP13 and IL1B promoters,
respectively, detected by in situ methylation analysis of chon-
drocytes obtained directly from human cartilage, strongly cor-
related with higher levels of gene expression. The methylation
status of these sites had a significant impact on promoter activ-
ities in chondrocytes, as revealed in transfection experiments
with site-directed CpG mutants in a CpG-free luciferase
reporter. Methylation of the 110 and 299 CpG sites, which
reside within a hypoxia-inducible factor (HIF) consensus motif
in the respective MMP13 and IL1B promoters, produced the
most marked suppression of their transcriptional activities.
Methylation of the 110 bp CpG site in the MMP13 promoter
inhibited its HIF-2-driven transactivation and decreased
HIF-2binding to theMMP13proximal promoter in chromatin
immunoprecipitation assays. In contrast to HIF-2, MMP13
transcriptional regulation by other positive (RUNX2, AP-1,
ELF3) and negative (Sp1, GATA1, and USF1) factors was not
affected by methylation status. However, unlike the MMP13
promoter, IL1B was not susceptible to HIF-2 transactivation,
indicating that the 299 CpG site in the IL1B promoter must
interact with other transcription factors tomodulate IL1B tran-
scriptional activity. Taken together, our data reveal that the
methylation of different CpG sites in the proximal promoters of
the human MMP13 and IL1B genes modulates their transcrip-
tion by distinct mechanisms.
Somatic cell phenotypes can be stably regulated by epige-
netic mechanisms, including DNA methylation (1, 2), which
may regulate gene transcription by recruiting chromatin
remodeling proteins and bymodulating the binding affinities of
specific transcription factors (3–7). In contrast to the more
dynamic and reversible histone modifications (1), CpG methy-
lation is generally stable in somatic cells throughout adult life
(8, 9). Investigations have mainly focused on the so-called CpG
islands but have ignored the contributions of sparse CpG sites.
Moreover, only a few reports have addressed how methylation
of individual CpG sites influences the promoter activity of a
specific gene (6, 10, 11), and the relative contributions of the
methylation status of each individual CpG site to the transcrip-
tional regulation of a given gene in vivo remain largely unex-
plored. In addition, although epigenetic gene regulation has
been broadly investigated in other contexts, little is known
about the specific impact of this mechanism of gene control in
musculoskeletal diseases (12–29).
Osteoarthritis (OA)3 is characterized by the progressive loss
of cartilage matrix, accompanied by deleterious changes in the
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synovium and subchondral bone (30, 31). In OA disease, chon-
drocytes undergo phenotypic changes with altered patterns of
gene expression that are stably transmitted to subsequent cell
generations (25, 32), suggesting the involvement of epigenetic
mechanisms in disease onset and progression. We previously
described a novel relationship between CpG demethylation
within the CpG-sparse promoters of the MMP3, -9, -13, and
ADAMTS4 genes and their aberrant, enhanced expression in
OA chondrocytes, although a direct relationship between the
methylation status of a specific CpG site and the respective
promoter activity was not investigated (25).We also found that
long term, repetitive stimulation of primary human chondro-
cytes with inflammatory cytokines induced demethylation of
specific CpG sites in the IL1B proximal promoter, leading to
increased and sustained IL1B expression (22). More recently,
Reynard et al. (24) reported CpG methylation-dependent reg-
ulation of growth differentiation factor 5 expression in OA,
along with direct evidence of suppressed gene activity in
response to methylation of its CpG islands in vitro.
Here, we report that the methylation of specific CpG sites in
the proximal promoters of both the human MMP13 and IL1B
genes correlates with their expression in cartilage and alters
their transcriptional activities in chondrocytes. In addition, we
provide the first evidence that binding to and transactivation of
the MMP13 promoter by hypoxia-inducible factor-2 (HIF-
2), also known as EPAS1 (endothelial PAS domain protein 1),
are controlled by these epigenetic events. Importantly, our in
vitro results correlate strongly with the in vivomethylation sta-
tus of the same individual CpG sites in the MMP13 and IL1B
promoters andwith their relative levels of gene activity in chon-
drocytes isolated directly from healthy and OA human
cartilage.
EXPERIMENTAL PROCEDURES
Human Primary Chondrocyte Isolation—Human articular
cartilage was obtained after hemiarthroplasty following femo-
ral neck fracture or total hip arthroplasty for OA with patient
consent and prior approval of the local Institutional Review
Board. Cartilage was dissected within 6 h of surgery, and
non-OA fractured neck of femur andOA human primary chon-
drocytes were isolated as described previously (22). Briefly, sam-
ples were obtained from the deep zone of cartilage from patients
with femoral neck fracture for isolation of non-OA/healthy chon-
drocytes,whereascartilagepiecesadjacent toweight-bearingareas
of OA femoral heads (lacking surface zones) were harvested to
obtainOAchondrocytes. Cartilage sampleswere then cut in small
fragments and digested with 10% trypsin (Lonza) in PBS for 30
min, followedbysequentialdigestions in1mg/mlofhyaluronidase
(Sigma-Aldrich) inPBS for 15min, and in10mg/mlof collagenase
B (RocheApplied Science) in-modified Eagle’smedium (Sigma-
Aldrich) for 12–15 h at 37 °C. Following isolation, the chondro-
cyteswereeither subjected tobisulfitepyrosequencingorplaced in
primary culture.
Pyrosequencing—Genomic DNA extracted directly from
neck of femur andOAchondrocytes or from cultured chondro-
cytes was treated with sodium bisulfite to convert unmethyl-
ated cytosine in CpG sites to uracil using the EZDNAmethyla-
tion Gold kit (Zymo Research). PCR and sequencing primers
for pyrosequencing were designed using the Biotage Assay
Design Software (version 2.0; Table 1). PCR was performed
with Premium® PCRSupermixHigh Fidelity (Invitrogen). Pyro-
sequencing reactions were run in the PyroMark Q96 MD sys-
tem (Qiagen), using 20l and 5l of the PCR products for CpG
methylation analysis of MMP13 and IL1B promoters, respec-
tively. Data are represented as percentage of methylation of
eachCpG site inOAor 5-aza-deoxycytidine (5-aza-dC)-treated
samples set against 100% in the non-OA or untreated controls.
Human Primary Chondrocyte Culture and 5-Aza-dC Treat-
ment—For culture and in vitro analysis, only deep-zone primary
non-OA chondrocytes were utilized, as described (21). Before
treatment, chondrocytes were cultured for 48 h at an average
density of 16 103 cells/cm2 in a 25-cm2 flask in 5ml of-mod-
ified Eagle’s medium supplemented with 10% FBS (Invitrogen),
1% insulin-transferrin-selenium (Sigma-Aldrich), 100 units/ml
of penicillin, and 100 g/ml of streptomycin (Lonza) and 100
g/ml of ascorbic acid (Sigma-Aldrich). The chondrocytes
were then left untreated (control) or incubated with 2 M
5-aza-dC and added freshly at twice weekly medium changes
for 4 to 5 weeks until confluence.
TABLE 1
Primer sequences for pyrosequencing
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DNA and RNA Extraction—Genomic DNA and total RNA
were extracted simultaneously from the harvested chondro-
cytes using AllPrep DNA/RNA mini kit (Qiagen). RNA was
reverse-transcribed with avian myeloblastosis virus reverse
transcriptase and combination of oligo(dT)15 and random
primers (Promega).
Quantitative RT-PCR—Gene expression was analyzed with
the ABI Prism 7500 gene detection system (Applied Biosystems)
using the following primers, designed using Primer Express soft-
ware (version 3.0; Applied Biosystems) to bracket exon-exon
boundaries: GAPDH, 5-CCAGGTGGTCTCCTCTGACTTC-
3 (forward) and 5-TCATACCAGGAAATGAGCTTGACA-3
(reverse); MMP13, 5-TTAAGGAGCATGGCGACTTCT-3
(forward) and 5-CCCAGGAGGAAAAGCATGAG-3 (reverse).
The IL1B primers were designed by and purchased from
PrimerDesign, Ltd. (Southampton, UK): 5-TGGCAATGA-
GGATGACTTGTTC-3 (forward) and 5-CTGTAGTGGT-
GGTCGGAGATT-3 (reverse). Reactions were performed in
triplicate, with GAPDH as the normalizing control gene. The
2Ct method was employed for relative quantification.
Plasmid Constructions—ACpG-free reporter vector, pCpG-
free-Luc vector, was generated according to the literature (33).
TheMMP13 promoter constructs spanning372/14,214/
14, and 86/14 bp of the human MMP13 promoter
sequence and containing seven, four, and one CpG sites, respec-
tively, were generated by PCR amplification, utilizing genomic
DNA from the human chondrocyte cell line C28/I2 (34) as a
template and the following PCR primers: MMP13(372/14),
5-CCGACTAGTGGAAGTAAACATGCCATCTTGATA-3
(forward); MMP13(214/14), 5-CCGACTAGTATTTTG-
CCAGATGGGTTTTG-3 (forward); MMP13(86/14), for-
ward: 5-CCGACTAGTCAAGTGACTAGGAAGTGGAA-
ACC-3; and reverse (common to all three MMP13 promoter
constructs): 5-CCGAAGCTTCCTGGGGACTGTTGTC-
TTT-3. Underlined letters indicate SpeI and HindIII recogni-
tion sequences in the forward and reverse primers, respectively.
The resultant PCR products were digested with SpeI and Hin-
dIII and transferred into the multiple cloning site of a pCpG-
free-Luc vector treated with the same enzymes using TaKaRa
DNA ligation kit (version 2.1; TaKaRa).
The human IL1B promoter constructs spanning 521/56,
276/56, and183/56bpandcontaining four, three, and two
CpG sites, respectively, were generated by PCR amplification
utilizing the following PCR primers: IL1B(521/56),
5-CCGACTAGTAGAGAGCTCCTGAGGCAGAG-3 (forward);
IL1B(276/56), 5-CCGACTAGTTGTGGACATCAACTGC-
ACAA-3 (forward); IL1B(183/56), 5-CCGACTAGTCCCT-
TCCATGAACCAGAGA-3 (forward); and common to all three
IL1B promoter constructs, 5-CCGAGATCTGGCTGAAGAG-
AATCCCAGAG-3 (reverse).Underlined letters indicateSpeIand
BglII recognition sequences on the forward and reverse primers,
respectively. The resultant PCR products were digested with SpeI
and BglII and transferred into the multiple cloning site of the
pCpGfree-Luc vector.
Point mutations of CpG sites were generated by converting
CG to TG by a two-step PCR mutagenesis approach as
described previously (35) using the primers shown in Table 2
and the wild type (WT) 214/14 bpMMP13 (MMP13–214)
or 521/56 bp IL1B (IL1B-521) promoter constructs, linear-
ized by double enzyme digestion by SacI andKpnI as templates.
After two-step PCR, the resulting products were digested with
SpeI/HindIII and SpeI/BglII for MMP13–214 and IL1B-521,
respectively, and cloned into the pCpGfree-Luc vector back-
bone treated with the same enzymes using TaKaRa DNA liga-
tion kit (version 2.1, TaKaRa). Promoter constructs with mul-
tiple CpG mutations were generated by a repeated two-step
PCRmutagenesis, utilizing different PCRmutagenesis primers
and linearized CpG-mutated MMP13–214 or IL1B-521 con-
struct as template. Expression vectors encoding ELF3, HIF1,
HIF-2, Sp1, RUNX2, NF-B, and AP-1 (cFos/cJun) were pur-
chased fromAddgene and/or described elsewhere (35–37). The
sequences of all constructswere confirmed byDNAsequencing
at the Cornell University Life Sciences Core Laboratories
Center.
In Vitro Methylation, Transfections, and Luciferase Assay—
The methylated plasmids were generated by incubating 1 g of
plasmid DNA with 4 units/l of the CpG methyltransferase,
M.SssI (Zymo Research) in reaction buffer supplemented with
1600 M S-adenosylmethionine according to the manufacturer’s
instructions. Completemethylation was verified by plasmidDNA
bisulfite modification and pyrosequencing using specific primers.
The methylated plasmid DNA was purified by the PureLink
Quick Plasmid Miniprep kit (Invitrogen). The methylated and
non-methylated vectors were then transfected in immortalized
human chondrocytes (C28/I2) seeded 24 h prior to transfection in
24-well tissue culture plates at 3.0  104 cells/well, using Lipo-
fectamine PLUSTM reagents as described (35). Briefly, transfec-
tions were carried out in triplicate in serum-free antibiotic-free
conditions, with a total of no more than 475 ng of plasmid DNA
per well, including 300 ng of non-methylated or methylated
MMP13 or IL1B luciferase reporter construct and the expression
vectors. The ratios of luciferase reporter construct to expression
vectorwere established by titrations to ensure that concentrations
of expressed transcription factors were not limiting to the pro-
moter transactivations under the conditions of the co-transfec-
tions. Reporter constructs were treated with DNA methyltrans-
ferase to methylate all available CpG sites in the promoters.
Luciferase assayswereperformedusing the luciferase assay system
(Promega) and detected using a LMaxII384 Luminometer system
(MolecularDevices).Unless otherwise specified, the firefly lucifer-
ase activities were normalized to the Renilla activity of pGL4.74-
hRluc-TK (Promega).
ChIP Assay—The ChIP-IT Express Enzymatic Kit (Active-
Motif) was used to perform ChIP assays according to the man-
ufacturer’s instructions with minor modifications, as described
(35), using C28/I2 chondrocytic cells co-transfected with non-
methylated or methylated pCpGfree-Luc-MMP13 vector
(214/14bp) and expression vectors encoding HA-tagged
HIF-2 or FLAG-tagged ELF3. At 24 h after transfection, pre-
cleared chromatinwas stored as assay input or incubated at 4 °C
overnight with 1.25g of rabbit anti-HA antibody (Invitrogen),
rabbit anti-FLAG antibody (Sigma), or normal rabbit IgG (Cell
Signaling). After reverse cross-linking and purification onDNA
mini-columns (Qiagen), the final DNA preparations were sub-
jected to quantitative PCR analysis using 5l of the elutedDNA
and the following primers specific for the transiently trans-
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fected MMP13 reporter construct: 5-TCAAATTCTACCAC-
AAACCACA-3 (forward) and 5-TAATATTCTTGGCAT-
CCTCCAT-3 (reverse). Primer efficiency was calculated uti-
lizing serial dilutions of the pooled inputDNA samples. For real
time PCR analysis, theCT of each sample was normalized to the
CT of the input sample (10%).
Statistical Analysis—Each data point is reported as the
means  S.E. of at least three independent experiments. Statis-
tical significance was evaluated using Student’s t test, with p
values of  0.05 considered significant.
RESULTS
Specific MMP13 and IL1B Proximal Promoter CpG Sites Are
Demethylated in OA Chondrocytes and Correlate with Higher
Levels of Gene Expression in OA Disease—We initially quanti-
fied the CpG methylation status of the 343/14 bp MMP13
and 299/13 bp IL1B proximal promoter sequences in
human primary chondrocytes isolated from articular cartilage
obtained from non-OA donors (n  12) and patients with OA
(n  17). Pyrosequencing analysis of the MMP13 promoter
revealed that five of the seven CpG sites contained in the prox-
imal promoter region were significantly demethylated in OA
compared with non-OA chondrocytes. The highest degree of
demethylation was observed at the110-bp CpG site (Fig. 1A).
The IL1B promoter was also significantly demethylated at the
299-bp CpG and 256-bp CpG sites in OA compared with
non-OA chondrocytes, whereas there was no significant differ-
ence in methylation status at the 20-bp CpG and 13-bp
CpG sites (Fig. 1B). Finally, the decreased methylation of the
MMP13 (Fig. 1C) and IL1B (Fig. 1D) proximal promoters cor-
related with higher levels of their mRNAs in OA chondrocytes
(Fig. 1C).
CpGDemethylation in Vitro Correlates with Enhanced Levels
of MMP13 and IL1B Gene Expression in Cultured Human Pri-
mary Chondrocytes—To determine the functional effects of
demethylating the CpG sites in theMMP13 and IL1B promot-
ers, we cultured human primary chondrocytes in the presence
or absence of 5-aza-dC, a CpG demethylating agent, as
described (22). Treatment with 5-aza-dC resulted in significant
TABLE 2
Primer sequences for two-step promoter mutagenesis
Name (location of mutated
CpG)/part of amplicon direction Sequence (5 to 3)a
MMP13–214-Mut1 (-14)
1st half (forward) TATGTGAGCAAACAGCAGATTAAAA
1st half (reverse) TTGTCTTTCCaCAGAGATTACCTTT
2nd half (forward) AAAGGTAATCTCTGtGGAAAGACAA
2nd half (reverse) AGACATCTCAAAGTATTCAGCATAGGT
MMP13–214-Mut2 (110)
1st half (forward)b AATAAATCTCTTTGTTCAGCTCTCTGTTTC
1st half (reverse) CTTACaTGGCGACTTTTTCTTTTCCCT
2nd half (forward) AGGGAAAAGAAAAAGTCGCCAtGTAAG
2nd half (reverse)c AGACATCTCAAAGTATTCAGCATAGGTGAT
MMP13–214-Mut3 (115)
1st half (forward)b AATAAATCTCTTTGTTCAGCTCTCTGTTTC
1st half (reverse) CTTACGTGGCaACTTTTTCTTTTCCCT
2nd half (forward) AGGGAAAAGAAAAAGTtGCCACGTAAG
2nd half (reverse)c AGACATCTCAAAGTATTCAGCATAGGTGAT
MMP13–214-Mut4 (135)
1st half (forward) ACCCAATAAATAATAAATCTCTTTGTTCAGCTCT
1st half (reverse) TTCTTTTCCCTCCCaAGTGTGGTTT
2nd half (forward) AAACCACACTtGGGAGGGAAAAGAA
2nd half (reverse) GACATCTCAAAGTATTCAGCATAGGTGATG
IL1B-521-Mut1 (13)
1st half (forward)d TTGTTTATGTGAGCAAACAGCA
1st half (reverse) CCTTGTGCCTCaAAGAGGTT
2nd half (forward) AACCTCTTtGAGGCACAAGG
2nd half (reverse)e CCAGCCTCACAGACATCTCA
IL1B-521-Mut2 (20)
1st half (forward)d TTGTTTATGTGAGCAAACAGCA
1st half (reverse) CCCTCaCTGTTTTTATGGCTTT
2nd half (forward) AAAGCCATAAAAACAGtGAGGG
2nd half (reverse)e CCAGCCTCACAGACATCTCA
IL1B-521-Mut3 (256)
1st half (forward) TTTGTTTATGTGAGCAAACAGCAG
1st half (reverse) TTTTCCTGACAATCaTTGTGCAGT
2nd half (forward) ACTGCACAAtGATTGTCAGGAAAA
2nd half (reverse) TGCCATCTTCCAGAGGGTAG
IL1B-521-Mut4 (299)
1st half (forward) TATGTGAGCAAACAGCAGATTAAAAG
1st half (reverse) AATACTGGATTTTCCCACaTTAGAAG
2nd half (forward) CTTCTAAtGTGGGAAAATCCAGTATT
2nd half (reverse) ACTAAGCTTAAGATCTGGCTGAAGAG
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demethylation of the CpG sites in the MMP13 promoter at
343 bp, 115 bp, 110 bp, and 14 bp (Fig. 2A). In the IL1B
promoter, significant loss of methylation occurred at the 299
bp CpG after 5-aza-dC treatment (Fig. 2B). In accordance with
these results, we had reported previously thatMMP13 and IL1B
mRNA levels increased by 2- and 5-fold, respectively, in
response to treatment with 5-aza-dC (22, 38).
Methylation of Unique CpG Sites in the Proximal Human
MMP13 and IL1B Gene Promoters Directly Affects Transcrip-
tional Activities—We next investigated the contribution of
each of the methylation-sensitive CpG sites to MMP13 and
IL1B promoter activities using aCpG-free reporter system. The
activities of deletion constructs of theMMP13 promoter, span-
ning 372/14, 214/14, and 86/14 bp, were signifi-
cantly reduced in their methylated state (Fig. 3A). Next, we
generated mutant constructs of the 214/14-bp MMP13
promoter harboring site-specific CpG mutation(s), replacing
unique cytosine (C) with thymine (T) residues, as indicated in
Fig. 3B. A single CpG mutation at 110 bp (110 mt) signifi-
cantly decreased promoter activity comparedwith theWTpro-
moter; in contrast, no other individual CpG mutant caused a
significant change in MMP13 promoter activity. In addition,
methylation significantly suppressed the activities of all single
CpG mutants except for the 110 mt and 14 mt (Fig. 3B).
Moreover, a triple CpG mutant construct (135/115/14
mt), which preserves the 110 bp CpG site, retained promoter
activity comparable with WT; all other triple mutants with a
mutated110 bpCpG site showed significantly decreased pro-
moter activity (Fig. 3C). Importantly, CpG methylation treat-
ment of the 135/115/14-mt construct significantly
decreased reporter activity. These results indicate that the
methylation status of the 110-bp CpG is crucial for MMP13
promoter activity. In contrast, activity of themethylated135/
110/14-mt construct, which only preserves the 115-bp
CpG site, increased by 3.7-fold (Fig. 3C).
We also generated three IL1B promoter constructs. Methyl-
ation treatment significantly decreased the activities of theWT
521/56 and 276/56 reporter constructs, with no signif-
icant effect on the183/56-bp promoter (Fig. 3D). Single and
triple CpG mutant constructs of the 521/56WT IL1B pro-
moter revealed that a single CpG mutation at 299 bp (299
FIGURE 1. Demethylation of specific MMP13 and IL1B proximal promoter
CpG sites in OA chondrocytes correlates with higher levels of gene
expression in OA disease. Bisulfite pyrosequencing analysis was performed
to determine the relative methylation status of the indicated CpG sites on the
(A) MMP13 or (B) IL1B proximal promoter sequences in healthy (fractured neck
of femur (NOF; n  12) and OA (n  17) human chondrocytes isolated directly
from cartilage. Data are represented as percentage of methylation in OA sam-
ples relative to that in non-OA specimens set at 100% for each CpG site.
MMP13 (C) or IL1B (D) mRNA was analyzed by quantitative RT-PCR and nor-
malized against GAPDH. All of the data are shown as means  S.E. (*, p  0.05;
**, p  0.01; ***, p  0.001).
FIGURE 2. CpG demethylation in vitro correlates with enhanced levels of
MMP13 and IL1B gene expression in cultured human primary chondro-
cytes. Primary human chondrocytes were cultured without or with 5-aza-dC
and the CpG methylation status of the MMP13 proximal promoter (A) or the
IL1B proximal promoter (B) was analyzed. All data are shown as means  S.E.
and represented as percentage of methylation in the 5-aza-dC-treated cells
relative to that in the non-treated control cells set at 100% for each CpG site
(*, p  0.05).
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mt) significantly decreased promoter activity, whereas the
256-bp CpG mutant was significantly more active than WT;
mutations of the other twoCpG sites had no effect on promoter
activity (Fig. 3E). Among the triple CpGmutants with only one
intact CpG site, the basal activity of the 256/20/13-mt
promoter did not change, whereas the basal activities of all con-
structs containing a mutated 299-bp CpG decreased signifi-
cantly (Fig. 3F). Furthermore, methylation treatment signifi-
cantly decreased the activity of the 256/20/13 mutant
(Fig. 3F). These results indicate that, similar to the 110-bp
CpG site in the MMP13 promoter, the methylation status of
one CpG at299 bp in the IL1B promoter uniquely impacts on
its transcriptional activity.
CpG Methylation Impairs HIF-2-driven MMP13 Promoter
Transactivation but Not IL1B Promoter Activation—CpG
methylation may regulate gene transcriptional activities by dif-
ferentially and directly modulating the binding affinities of
trans-acting factors (6). Hence, we next investigated the effects
of CpG methylation status on the actions of MMP13 trans-
acting factors selected based on previous reports (35, 39–44)
and on bioinformatic analyses using the Transcription Element
Search System (Fig. 4A). In agreement with prior work (43, 44),
HIF-2 overexpression increased the activity of the nonmethy-
lated WT 214/14-bp promoter construct; interestingly,
CpG methylation significantly attenuated this HIF-2-medi-
ated promoter activation (Fig. 4B). In addition, HIF-2 overex-
pression did not significantly activate the nonmethylated
110-mt construct (Fig. 4B), whereas HIF-2 transactivated
the non methylated triple mutant with an intact 110-bp CpG
to an extent comparablewith theWTconstruct. All other triple
mutant constructs showed decreased HIF-2-driven transacti-
vation, compared with the WT reporter construct (Fig. 4C).
Methylation treatment of the triple mutant with an intact
110-bp CpG significantly decreasedMMP13 promoter activ-
ity in response to HIF-2 overexpression (Fig. 4C). Together,
these results indicate that targeted 110-bp CpG methylation
FIGURE 3. Methylation of unique CpG sites in the proximal human MMP13 and IL1B gene promoters directly affects transcriptional activity. Basal
activities of MMP13 and IL1B promoter constructs with deletions from 5 ends or specific CpG mutation(s) were analyzed with (Meth, closed bars) or without
(Meth, open bars) CpG methylation treatment in luciferase assays performed in C28/I2 chondrocytes. MMP13 promoter activity was analyzed in cells trans-
fected with WT 372/14, 214/14, and 86/14-bp constructs (A), 214/14-bp constructs containing single CpG mutations (B), and 214/14-bp
promoter constructs containing triple CpG mutations (C), leaving only one intact CpG site. IL1B promoter activity was analyzed in cells transfected with
521/56, 276/56, and 183/56-bp constructs (D), 521/56-bp constructs with single CpG mutations (E), and 521/56-bp constructs with triple-
CpG mutations (F), leaving only one intact CpG site. All data are shown as means  S.E. (*, p  0.05; **, p  0.01; ***, p  0.001). Luc, luciferase. N.S., not
significant.
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impairs HIF-2 transactivation of the MMP13 promoter in
vitro.
To assess the specificity of the above effects of HIF-2, we
interrogated the dependence of activities of multiple transcrip-
tion factors on CpG site-specific methylation of the MMP13
promoter. Overexpression of RUNX2, ELF3, or AP-1 (c-Fos/c-
Jun) activated theMMP13 promoter constructs as shown pre-
viously (35, 42); but in contrast to our resultswithHIF-2, these
transactivations were unaffected by any CpG site mutation or
by alteration ofmethylation status (data not shown).Moreover,
in contrast to HIF-2, HIF-1 had no significant effect when
co-transfected with any MMP13 promoter construct in the
absence or presence ofmethylation (data not shown). Similarly,
overexpressing Sp1, USF-1, or GATA-1 had no effect on
MMP13 promoter activity and did not correlate with mutation
or methylation of any specific CpG site (data not shown).
We also investigated the effects of CpG methylation on the
actions of candidate IL1B trans-acting factors (Fig. 4D). HIF-2
overexpression had no significant effect on IL1B promoter
activity (Fig. 4, E and F). In contrast, HIF-1 or NF-B (p65/
p50) overexpression significantly increased IL1B promoter
activity, but this enhancement was independent of mutation of
any CpG site or alteration of CpG methylation status (data not
shown). Furthermore, overexpression of USF-1 or the combi-
FIGURE 4. CpG methylation impairs the HIF-2-driven MMP13 promoter transactivation. Shown is the schematic representation of the proximal human
MMP13 (42) (A) and IL1B (D) promoter sequences. Putative binding sites for trans-acting factors are underlined. Methylated (Meth; closed bars) or non-
methylated (Meth; open bars) MMP13 promoter constructs with single CpG mutations (B) or triple CpG mutations (C) were co-transfected with the empty
control vector (pcDNA3) or with the HIF-2 expression vector. Methylated (Meth; closed bars) or non-methylated (Meth; open bars) IL1B promoter constructs
with single CpG mutations (E) or triple CpG mutations (F) were co-transfected with the empty control vector (pcDNA3) or with the HIF-2 expression vector. All
data are shown as means  S.E. Luc, luciferase.
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nation of Single-minded (Sim) 2 and aryl hydrocarbon receptor
nuclear translocator (ARNT) significantly repressed IL1B pro-
moter activity, but the latter responses were not significantly
changed by the methylation status of the promoter or by tar-
geted mutation of any CpG site (data not shown).
CpGMethylation Attenuates HIF-2 Binding to the MMP13
Promoter—Given the results above, we investigated whether
CpGmethylation status directly affectedHIF-2 binding to the
proximal MMP13 promoter in ChIP assays. In the context of
endogenous chromatin, methylating/demethylating agents
would impact transcription affecting not only in the proximal
promoter region analyzed in our study but also distal
sequences, therefore introducing further complexity to the
analysis. Hence, to avoid confounding effects of CpG sites in
distal MMP13 promoter regions and their contributions to
overall endogenous chromatin structure, ChIP assays were per-
formed in chondrocytes transfected with methylated and non-
methylated WT 214/14-bp MMP13 constructs in combi-
nation with expression vectors encoding HA-tagged HIF-2 or
FLAG-tagged ELF3; and MMP13 promoter binding was ana-
lyzed with specific PCR primers that only recognize the tran-
siently transfected promoter constructs, as described in the
“Experimental Procedures.” ChIP assays revealed thatmethyla-
tion treatment significantly reduced HIF-2 binding to the
MMP13 proximal promoter (Fig. 5A), in agreement with our
results showing decreased HIF-2-drivenMMP13 transactiva-
tion after methylation treatment of the WT and/or mutant
MMP13 reporter constructs (Fig. 4, B and C). In contrast, as a
control, ELF3 binding to the proximal MMP13 promoter was
not affected by promoter methylation status (Fig. 5B), in
accordance with our results showing that ELF3-drivenMMP13
transactivation is methylation-insensitive, as indicated above.
Our results show that CpG methylation of the MMP13 proxi-
mal promoter specifically impairs HIF-2-driven promoter
activation by altering its binding to DNA.
DISCUSSION
MMP-13, or collagenase 3, is the major type II collagen-de-
grading enzyme that drives erosion of the cartilage collagen
network in OA disease (45–48). This enzyme plays essential
roles in extracellular matrix remodeling in the late hyper-
trophic zone of the growth plate prior to endochondral ossifi-
cation, but articular chondrocytes express low basal MMP-13
levels under normal, physiological conditions in vivo (49). High
levels and activity of MMP-13 and other matrix-degrading
enzymes in OA chondrocytes are due in part to their activated
state in response to enhanced stress and inflammatory signal-
ing (reviewed in Ref. 39). MMP13 transcription is subject to
regulation by a number of transcription factors, including
ELF3, RUNX2, AP-1 (cFos/cJun), p130cas nuclear matrix tran-
scription factor 4 (NMP-4), the canonical NF-B subunits p65/
p50, and HIF-2 (35, 40–44, 50). NF-B also plays a major role
in increased IL1B expression in various cell types under stress/
proinflammatory conditions by directly activating the IL1B
promoter (51, 52). Moreover, as shown previously, NF-B
modulates gene expression in some contexts via epigenetic
mechanisms, affecting the level of CpG demethylation (53).
Our previous studies showed epigenetic changes associated
with abnormalMMP13 and IL1B gene expression in chondro-
cytes of OA cartilage (25) and in long term cytokine-treated
human primary chondrocyte cultures (22). Although other
studies have also described associations between CpG methy-
lation status and deregulation of OA-associated genes (23, 24,
54), this does not appear to be the case for all genes in human
chondrocytes (26, 55). However, most previous studies of OA-
associated genes have investigated their CpG islands, ignoring
the fact that 5-UTRwith non-islandCpG sitesmay also impact
functionally on gene regulation by alterations in CpGmethyla-
tion status (56). Indeed, there is a paucity of studies that have
functionally analyzed alterations in promoter activity induced
by the methylation of a single CpG site (6, 10, 11). In our study,
the use of a CpG-free luciferase reporter gene system (33) facil-
itated the investigation of the direct cause-and-effect relation-
ships betweenCpGmethylation and altered promoter activities
of specific genes, and the dissection of the relative contribution
of individual CpG sites to the transcriptional control of a given
gene.
Here, we have shown thatmethylation of uniqueCpG sites in
the proximalMMP13 and IL1B promoters regulates their tran-
scriptional activities in human chondrocytes via different
mechanisms (Fig. 6). We initially quantified the methylation
status of the promoters of the human genes in chondrocytes
isolated from normal andOA articular cartilage and found that
FIGURE 5. CpG methylation attenuates HIF-2 binding to the MMP13 pro-
moter. ChIP assays were performed using cell lysates of C28/I2 cells trans-
fected with methylated (Meth) or non-methylated (Meth) WT 214/
14-bp MMP13 promoter constructs and expression vectors encoding
HA-tagged HIF-2 (A) or FLAG-tagged ELF3 (B). At 24 h after transfection,
chromatin was cross-linked and enzymatically sheared, and after reverse
cross-linking of the DNA-protein complexes, the precleared lysates were
incubated with antibodies against HA, FLAG, or normal IgG overnight at 4 °C.
The HA-HIF-2 and FLAG-ELF3 binding to the human MMP13 promoter
region was analyzed by real time PCR, utilizing PCR primers bracketing the
transfected reporter vector boundaries. All data are shown as means  S.E.
and represented as fold-change versus IgG (*, p  0.05; ***, p  0.001).
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the 110-bp CpG and 299-bp CpG in the proximalMMP13
and IL1B promoters, respectively, were most subject to dem-
ethylation. Interestingly, 5-aza-dC treatment of human pri-
mary chondrocyte cultures induced demethylation of the same
CpG sites in MMP13 and IL1B promoters, accompanied with
increased expression of both genes. Although the possible
involvement of other pathways in promoter-activating effects
of 5-aza-dC cannot be excluded, these findings indicate that
each CpG site has a different sensitivity to demethylation and
that demethylation of specific CpG sites has the potential to
activate or derepressMMP13 and IL1B gene expression.
We directly investigated the cause-and-effect relationship
between the methylation of these specific CpG sites and the
transcriptional activities of MMP13 and IL1B promoters by
comparative analysis of their non-methylated and methylated
forms. The activities of WTMMP13 and IL1B promoters with
methylated CpG sites were reduced compared with their non-
methylated counterparts; this was true even for promoter con-
structs containing longer 5-flanking promoter sequences,
indicating that themethylation of sparse CpG sites in the prox-
imal promoters of these two genes can have a direct suppressive
effect on transcriptional activity. In addition, analyses of single
and triple CpGmutants within the proximalMMP13 and IL1B
promoters further clarified that their respective 110-bp CpG
and 299-bp CpG sites have key roles in the methylation-de-
pendent regulation of these two genes in human chondrocytes.
Importantly, the latter specific CpG sites correspond to the
most demethylated CpG sites in OA chondrocytes ex vivo and
in 5-aza-dC-treated primary chondrocytes in vitro.
The 110-bp CpG and 299-bp CpG sites in the proximal
promoters of the humanMMP13 and IL1B genes contain puta-
tive ACGT hypoxia-responsive element consensus core
sequences, which in some contexts respond to bothHIF-1 and
HIF-2 (57–61). HIF-2, but not HIF-1, controls MMP-13
expression in chondrocytes in vitro and in vivo and regulates
both endochondral ossification processes and cartilage
destruction in OA disease (43, 44). HIF-2, the gene product of
EPAS1, is an IL-1-inducible member of the basic helix-loop-
helix Per-ARNT-Sim (bHLH-PAS) family of transcription fac-
tors that directly targets the hypoxia-responsive elements
within theCOL10A1,MMP13, andVEGFA promoters in chon-
drocytic ATDC5 cells and inHeLa cells (43). HIF-2 binding to
the endogenous MMP13 promoter containing the proximal
hypoxia-responsive element has been demonstrated previously
by ChIP in vivo and by EMSA in vitro (43). In addition, HIF-2-
mediatedMMP13 transcriptional control has been established
both in vitro and in vivo (43, 44). Moreover, enforced expres-
sion of HIF-2 in vivo has been shown to result in enhanced
cartilage damage in association with enhanced MMP-13
expression. Furthermore, Epas1/ mice, which are haploin-
sufficient inHIF-2, have reduced levels ofMMP13mRNAand
are resistant to surgically or chemically induced knee OA dis-
ease (44).
Here, we have shown that enforcedHIF-2 expression trans-
activates a nonmethylated WT MMP13 promoter construct
and that its transactivating effect is reduced by CpG methyla-
tion. Moreover, HIF-2-driven MMP13 activation is solely
dependent on the presence of the 110-bp CpG site in the
proximal promoter of the gene and targeted methylation of the
110-bp CpG also diminishes MMP13 promoter transactiva-
tion by HIF-2, suggesting that demethylation of this specific
CpG site is essential for HIF-2-mediated MMP13 promoter
activation and contributes to increased MMP13 expression in
OA chondrocytes. Consistent with our finding that CpGmeth-
ylation treatment suppresses HIF-2-driven activation of the
MMP13 promoter, ChIP assays performed with cells co-trans-
fected with HIF-2 and a MMP13 promoter construct with a
methylation-resistant reporter gene revealed that targeted
methylation of the MMP13 proximal promoter significantly
decreased HIF-2 binding affinity.
In addition to our observations, Bui et al. (10) recently
reported that the same 110-bp CpG site (positioned at 104
in their report, based on the selected TSS) affects MMP13
transactivation via basal and IL1--induced CREB recruitment
in vitro. The latter observations, taken together with our results
demonstrating that HIF-2-driven MMP13 control depends
upon themethylation status of the110-bpCpG site, highlight
the multifaceted importance of the methylation status of this
specific CpG site in the control of MMP13 transcription by
different trans-acting factors responding to diverse disease-as-
sociated environmental cues and thereby revealing its poten-
tially important role in the dysregulation ofMMP13 expression
observed in OA cartilage.
In contrast to theMMP13 promoter, HIF-2 had no activat-
ing effect on the IL1B promoter, even though the critical
FIGURE 6. Scheme of CpG sites on the proximal MMP13 and IL1B promot-
ers. The CpG sites are indicated by open ovals. The positive () and negative
() transcription factors that bind to these promoters are indicated with
arrows above and below, respectively. In co-transfection experiments, only
HIF-2-driven MMP13 promoter activity was modulated by CpG methylation
status and methylation attenuated HIF-2 binding to the 110 CpG in ChIP
assays. On the IL1B promoter, HIF-1 and NF-B, but not HIF-2, enhanced
transcriptional activity, but there was no relationship with CpG methylation
status for activities of the transcription factors studied.
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299-bp CpG for IL1B promoter activity is located within a
putative hypoxia-responsive element core sequence (Fig. 4D), a
non-canonical “E-box-like” sequence (CANNTG), to which
several bHLH-PAS family transcription factors can bind. A het-
erodimer of two bHLH-PAS familymembers, Sim2 andARNT,
binds to non-canonical E-boxes, repressing (62, 63) or activat-
ing (64) transcription depending upon the promoter and cellu-
lar contexts. However, overexpression of Sim2 and ARNT
repressed IL1B promoter activity independent of CpG methy-
lation status. Although we found that the 299-bp CpG is
essential for IL1B promoter activity and that its demethylation
correlates with enhanced IL1B gene expression in human pri-
mary chondrocytes ex vivo and in vitro, mutation of this site
does not attenuate IL1B promoter transactivation by NF-B.
Early studies in myeloid cell lines demonstrated that two other
functional NF-B sites, which exist upstream in the IL1B pro-
moter, were influenced by CREB, whereas mutation of the
299-bp NF-B site attenuated transactivation by C/EBP but
not by CREB (51, 52). Whether methylation at 299-bp CpG
directly affects the binding and activities of other bHLH family
members or it modulates IL1B transcription via other indirect
mechanisms merits future investigation.
Our finding that methylation of the 115-bp CpG site
enhancesMMP13promoter activity (Fig. 3C), as opposed to the
inhibitory effect of 110-bp CpG methylation, suggests alter-
native mechanisms, as reported for half-Cre sequences, where
CpG methylation creates C/EBP binding sites and activates
gene expression (6). The 115-bp CpG overlaps a GATA-1
binding sequence, although the inhibitory effect of GATA-1
overexpression on MMP13 promoter activity was not altered
bymethylation status (data not shown). Further analysis will be
required to elucidate the role of the115-bp CpG site inmeth-
ylation-dependentMMP13 promoter activation.
Interestingly, treatment with 5-aza-dC in vitro produced a
more marked decrease in the methylation of CpG sites in the
proximal MMP13 and IL1B promoters than that observed ex
vivo comparing OA and non-OA articular chondrocytes. How-
ever, whereas OA chondrocytes showed 25-fold and 800-fold
MMP13 and IL1B gene expression compared with non-OA
chondrocytes, the MMP13 and IL-1 expression levels were
only modestly elevated by the more pronounced 5-aza-dC-in-
duced demethylation in vitro. Moreover, in reporter assays, dif-
ferences in promoter activities with or without methylation
were alsomodest evenwhen themethylation status of a specific
CpGwas all or none in the reporter constructs. Taken together,
our observations suggest that even a small change in CpG
methylation status may have a significant impact on gene
expression in vivo, where CpG methylation is likely to be a
contributing factor not only by altering the binding of trans-
acting factors, but also by acting together with histone-modify-
ing, chromatin-remodeling activities and other transcriptional
regulatory elements. Indeed, 5-aza-dC treatment of primary
cultures does not necessarily reflect the more complex in vivo
physiological or pathological condition, wheremore prolonged
exposure to different stimuli may induce not only differential
methylation patterns but also other epigenetic changes that
may be absent in our chondrocyte culture systems and reporter
assays. Furthermore, analysis of the cell populations in vivo/ex
vivo is limited in that cell-to-cell variability is not taken into
account, whereas in vitro studies are performed with synchro-
nized cells. Hence, limitations in current methylation and epi-
genomic mechanistic studies stem from the lack of technology
and models that more precisely reflect the in vivo scenario.
Techniques that allow for specific modulation of CpG methy-
lation patterns in vivo are required, therefore, for a better
understanding of the precise contributions of this means of
transcriptional control (65, 66).
In summary, we have investigated the relative contributions
of themethylation status of individual CpG sites in theMMP13
and IL1B proximal promoters tomodulation of their transcrip-
tional activities and found thatmethylation of uniqueCpG sites
has promoter-specific effects. Moreover, we show that the
DNAbinding and transactivation activity ofHIF-2, a key tran-
scription factor in MMP13 gene regulation, is prevented by
methylating only one unique CpG site in the proximalMMP13
promoter. Although the use of epigenetic inhibitors as cancer
therapies is closer to reality than their use in musculoskeletal
diseases (67), specific targeting of DNAmethylation may even-
tually represent a potential therapeutic strategy to prevent or
delay OA disease progression by suppressing the activities of
catabolic genes causing cartilage matrix destruction. Our find-
ingsmay also suggest the utility ofmethylationmarks as advan-
tageous early diagnostic markers of OA disease.
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